Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04869501 No longer available - Cancer Clinical Trials

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.

NCT ID: NCT03529539 No longer available - Cancer Clinical Trials

Expanded Access for PSV Personalized Oncolytic Viruses

PSV
Start date: n/a
Phase:
Study type: Expanded Access

A compassionate use, expanded access protocol for patients who have exhausted all standard therapy having progressed on chemotherapy and immunotherapy.

NCT ID: NCT03066661 No longer available - Clinical trials for Cancers With NTRK, ROS1, or ALK Gene Fusions

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

NCT ID: NCT02174679 No longer available - Clinical trials for Neuroendocrine Tumors

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Start date: n/a
Phase:
Study type: Expanded Access

To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

NCT ID: NCT01432483 No longer available - Cancer Clinical Trials

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.

NCT ID: NCT00805337 No longer available - Cancer Clinical Trials

Low Levels of Electromagnetic Fields to Treat Advanced Cancer

ADLG3
Start date: n/a
Phase: N/A
Study type: Expanded Access

Following the discovery of tumor-specific frequencies in patients with advanced cancer, compassionate treatment with tumor-specific frequencies administered at levels that are significantly below the levels generated by cell phone will be offered to patients with limited therapeutic options.